Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Combined MRI/mammography, mammography and unscreened BRCA2 mutation carriers survival from diagnosis

From: Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality

  Number 10-year survival all causes (95 % CI) Log Rank (Mantel-Cox) P value for overall survival compared to unscreened 10-year survival breast cancer (95 % CI) Log Rank (Mantel-Cox) P value overall survival compared to unscreened
Unscreened 274 70.8 (62.2 to 79.4)   74.6 (66.6 to 82.6)  
MRI/mammography 34 100 % 0.026 100 % 0.035
6 prevalent
26 incident
2 Interval
Mammography 53 85.5 (72.6 to 98.4) 0.142 85.5 (72.6 to 98.4) 0.196
9 prevalent
36 incident
8 Interval
Any screening 87 (5 detected on mammography only in MRI group and 6 with both modalities) 89.5 (79.5 to 99.5) 0.017 89.5 (79.5 to 99.5) 0.029